Insider Selling: Zai Lab (NASDAQ:ZLAB) CEO Sells 46,387 Shares of Stock

Key Points

• Ying Du, CEO of Zai Lab Limited, sold 46,387 shares of the company's stock on August 13th for approximately $1.65 million, reducing his ownership by nearly 8%.
• Zai Lab's shares were down to $34.93 during trading, with a 52-week low of $16.03 and high of $44.34, reflecting volatility in the stock's performance.
• The company met earnings expectations with a reported EPS of ($0.37) for the latest quarter but reported revenue of $109.98 million, below analysts' expectations of $125.66 million.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 46,387 shares of Zai Lab stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $35.47, for a total value of $1,645,346.89. Following the completion of the transaction, the chief executive officer owned 536,962 shares of the company's stock, valued at approximately $19,046,042.14. The trade was a 7.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Ying Du also recently made the following trade(s):

• On Friday, August 8th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.74, for a total value of $1,737,000.00.
• On Monday, August 11th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $34.64, for a total transaction of $1,732,000.00.
• On Wednesday, July 2nd, Ying Du sold 7,072 shares of Zai Lab stock. The stock was sold at an average price of $35.23, for a total transaction of $249,146.56.
• On Monday, June 30th, Ying Du sold 6,918 shares of Zai Lab stock. The shares were sold at an average price of $35.52, for a total transaction of $245,727.36.
• On Thursday, June 26th, Ying Du sold 23,669 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total transaction of $855,160.97.

Zai Lab Stock Down 0.7%

ZLAB stock traded down $0.25 during midday trading on Tuesday, reaching $35.44. The company had a trading volume of 320,371 shares, compared to its average volume of 740,701. The firm has a market capitalization of $3.94 billion, a PE ratio of -17.37 and a beta of 1.03. The stock has a 50 day moving average price of $36.54 and a 200 day moving average price of $33.66. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $16.83 and a fifty-two week high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.37). The business had revenue of $109.98 million during the quarter, compared to analyst estimates of $125.66 million. Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%. Zai Lab has set its FY 2025 guidance at EPS. Research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Analyst Upgrades and Downgrades

ZLAB has been the topic of several recent analyst reports. Wall Street Zen downgraded Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Leerink Partners set a $75.00 price objective on Zai Lab and gave the company an "outperform" rating in a report on Monday, June 30th. Finally, Citigroup reaffirmed a "buy" rating and set a $69.00 target price (up from $66.00) on shares of Zai Lab in a report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $57.22.

Institutional Trading of Zai Lab

Large investors have recently added to or reduced their stakes in the company. Kingsview Wealth Management LLC increased its holdings in Zai Lab by 6.0% in the 1st quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company's stock valued at $337,000 after buying an additional 529 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Zai Lab during the 4th quarter valued at about $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Zai Lab by 2.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock valued at $1,496,000 after acquiring an additional 1,200 shares during the period. Walleye Capital LLC increased its stake in Zai Lab by 6.4% in the first quarter. Walleye Capital LLC now owns 22,276 shares of the company's stock valued at $805,000 after acquiring an additional 1,338 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in Zai Lab by 13.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company's stock worth $453,000 after purchasing an additional 1,483 shares in the last quarter. 41.65% of the stock is owned by institutional investors and hedge funds.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.